TOP HEADLINES

Featured Story

  • Cambridge scientists find molecular catalyst behind Alzheimer's

    U.K. researchers may have identified a catalytic trigger for the onset of Alzheimer's disease--a finding that could help doctors diagnose the disease earlier and potentially pave the way for a new class of drugs desperately needed to help treat the debilitating disease.

UPDATED: Lundbeck depression drug improves attention, memory in animal model

Danish pharmaceutical group Lundbeck on Wednesday reported that its investigational depression drug vortioxetine improved a number of cognitive functions in preclinical animal models.

Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease

Alnylam Pharmaceuticals has reported upbeat preclinical findings in a proof-of-concept study for its RNAi therapeutic program to treat porphyria, including acute intermittent porphyria, a rare genetic metabolic disorder caused by an enzyme deficiency.

Drug boosts effectiveness of radiation therapy for brain tumors

An enzyme inhibitor that helps repair DNA damage may provide a new way to boost the effectiveness of radiation therapy for a lethal type of brain cancer.

New agent halts progression of childhood bone cancer in preclinical study

A new drug developed by researchers at Georgetown University Medical Center may be able to stop the progression of a rare bone cancer that affects children and adolescents.

Researchers pinpoint protein involved in cancer cell death

MIT researchers may have discovered a key protein involved in cell death--one that could help kill remaining cancer cells after chemotherapy.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

A slew of potential bidders will likely bid for Panasonic's healthcare unit, boosting the Japanese consumer electronics giant's chances of raising as much as $1 billion to grow its med tech offerings.

FierceMedicalDevices

Roche won the FDA's blessing to market a hemoglobin-based diabetes diagnostic, the latest advance in testing for the disease and the first assay of its kind approved in the U.S.